Recent advances in IgG4-related kidney disease

Mod Rheumatol. 2023 Mar 2;33(2):242-251. doi: 10.1093/mr/roac065.

Abstract

Recent advances in the management and understanding of immunoglobulin (Ig)G4-related kidney disease (RKD) have emphasized the importance of urgent treatment in IgG4-related tubulointerstitial nephritis. On the other hand, to avoid long-term glucocorticoid toxicity, strategies for early withdrawal of steroids or combination of immunosuppressants, such as rituximab, and the minimum dose of steroids have been pursued. However, disease recurrence after reducing or stopping steroid therapy hampers early withdrawal of glucocorticoid maintenance therapy. In addition, knowledge has accumulated in diagnostic approaches including differential diagnosis of anti-neutrophil cytoplasmic antibodies-associated vasculitis, idiopathic multicentric Castleman's disease, and Rosai-Dorfman disease with kidney lesion, which leads to earlier and precise diagnosis of IgG4-RKD. This review summarizes recent progress in the differential diagnosis of IgG4-RKD and related treatment strategies and recent topics of hypocomplementaemia, membranous glomerulonephritis, and IgG4-related pyelitis and periureteral lesion.

Keywords: IgG4-related disease; IgG4-related kidney disease; classification criteria; hypocomplementaemia; membranous glomerulonephritis.

Publication types

  • Review

MeSH terms

  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulin G
  • Immunoglobulin G4-Related Disease* / diagnosis
  • Immunoglobulin G4-Related Disease* / drug therapy
  • Immunoglobulin G4-Related Disease* / pathology
  • Kidney / pathology
  • Nephritis, Interstitial* / diagnosis

Substances

  • Glucocorticoids
  • Immunoglobulin G